DISTINGUISHED FACULTY:

John L. Allinson, FIBMS, Vice President, Biomarker Laboratory Services, ICON Development Solutions

Michael Amos, Ph.D., Scientific Advisor, Chemical Science & Technology Laboratory, National Institute of Standards & Technology Measurement; Ex-Officio Member, Secretary’s Advisory Committee on Genetics Health and Society (SACGHS), Department of Health and Human Services
Samuel C. Blackman, M.D., Ph.D., Associate Director, Experimental Medicine/Oncology, Merck Research Laboratories

Massimo Cristofanilli, M.D., FACP, Professor and Chairman, Department of Medical Oncology; G. Morris Dorrance Jr. Endowed Chair in Medical Oncology, Fox Chase Cancer Center (FCCC)

Viswanath Devanarayan, Ph.D., Director, Global Exploratory Statistics, Abbott Laboratories

Giora Feuerstein, M.D., Assistant Vice President and Head, Discovery Translational Medicine, Wyeth Research

Mark Fidock, Ph.D., Head, Quantitative Biomarkers, Research Enabling Group, Pfizer Ltd.

Felix W. Frueh, Ph.D., Vice President, Research & Development, Personalized Medicine, Medco Health Solutions, Inc.

Andrew Grupe, Ph.D., Senior Director, Pharmacogenomics Research & Development, Celera Corporation

Darren Hodgson, M.D., Biomics Advisor, Oncology and Infection Therapy Area, AstraZeneca

Dave S.B. Hoon, Ph.D., Director, Department of Molecular Oncology, John Wayne Cancer Institute.

Francis Kalush, Ph.D., Network Leader, Diagnostics & Personalized Medicine, CDRH, U.S. Food and Drug Administration

Aaron B. Kantor, Ph.D., Chief Scientific Officer, Research and Development, Immune Tolerance Institute

Joe Keenan, Head, Sales and Marketing, Argutus Medical Ltd.

Geert J.C.M. Kolvenbag, M.D., Ph.D., Global Product Vice President, Oncology, AstraZeneca Pharmaceuticals, Inc.

Myla Lai-Goldman, M.D., Chief Executive Officer, CancerGuide Diagnostics, Inc.

Thomas M. Li, Ph.D., CTO and Senior Director, Technology Management, Roche Diagnostics

Robert McCormack, Ph.D., Director, Technology Assessment, Ortho Clinical Diagnostics, Veridex, LLC

Glenn A. Miller, Ph.D., Vice President and General Manager, Genzyme Analytical Services

Madhu Mondal, Ph.D., DABT, Head, Protein and Analytical Toxicology Laboratory, Investigative Toxicology/Preclinical Safety, Novartis Institutes of Biomedical Research, Inc.

Margaret Piper, Ph.D., MPH, Director, Genomics Resources, Technology Evaluation Center, Blue Cross Blue Shield Association

Bruce Quinn, M.D., Ph.D., Senior Health Policy Specialist, Foley Hoag; Former California Medical Director, NHIC

Donna Roscoe, Ph.D., Scientific Reviewer, DIHD/OIVD/CDRH/FDA

Allen D. Roses, M.D., Jefferson-Pilot Professor of Neurobiology and Neurology, Director, Deane Drug Discovery Institute, Duke University

Yaping Shou, M.D., Ph.D., Director, Oncology Biomarkers and Imaging, Biomarker Project Leader-Tasigna, Novartis Institutes for BioMedical Research

Alain Van Gool, Ph.D., Head, Molecular Profiling, Translational Medicine Research Centre Singapore, Merck Research Labs

John Wagner, M.D., Ph.D., Vice President, Clinical Pharmacology, Merck Research Labs

Yaning Wang, Ph.D., Team Leader, Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

David Wholley, Director, The Biomarkers Consortium, Foundation for the National Institutes of Health

Hans Winkler, Ph.D., Senior Director and Global Head, Oncology Biomarkers, Johnson & Johnson Pharmaceutical R&D